Njord Medtech - Atle & Freja Israel
| Reference number | |
| Coordinator | Njord International AB |
| Funding from Vinnova | SEK 100 000 |
| Project duration | November 2023 - November 2024 |
| Status | Completed |
| Venture | Cooperation between Sweden och Israel |
| Call | Planning grant for collaboration with Israel |
Important results from the project
To a large extent the project´s objectives were met. We have managed to bring Atle 180 to Israel with ongoing demonstrations in their healthcare facilities, albeit with a partner that was not intended at the start of the project. Furthermore, we have developed a first working prototype for a new product "Freja". However, we have not yet reached a level that allows us to start validating "Freja" in the Israeli healthcare system. The project also contributed to new established contacts.
Expected long term effects
Atle 180 is likely to be implemented in the Israeli healthcare system with a positive impact on the work environment and clinical productivity. Hopefully a new product will also reach the commercial stage.
Approach and implementation
The initial plan was to establish the partnership on site in Israel. Due to prevailing circumstances, the geographical location was changed to Sweden, Gothenburg. Clinical training was carried out with Atle 180. Thereafter a unit was sent to Israel for demonstrations and tests. Development of the prototype was carried out by project partners and another Swedish actor, Scanfil Åtvidaberg AB. Subsequently, initial validation has been carried out in Gothenburg.